One study, conducted by Goel et al. [38], analyzed the potential predictive values of cTn I and NT-proBNP in evaluation of cardiotoxicity in female patients with normal cardiac function and who received trastuzumab for breast cancer; the authors reported elevated NT-proBNP levels in a substantial proportion of patients with normal LVEFs, but no significant changes in cTn I levels, suggesting that this might reflect the mechanism of cardiotoxicity as a subclinical cardiac strain. Here, TNNI3 is linked to breast cancer.